Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

LGC Acquires Quotient’s Bioanalytical Business

Published: Friday, January 04, 2013
Last Updated: Friday, January 04, 2013
Bookmark and Share
Acquisition will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector.

LGC and Quotient Bioresearch has announced that they have reached agreement on the sale by Quotient of its Bioanalytical Sciences division to LGC.

Quotient Bioanalytical Sciences is a leading provider of bioanalytical services across the fields of small molecules, biomarkers, biopharmaceuticals and microbiological testing to customers in the pharmaceutical and biotechnology sectors. It is based at Fordham, Cambridgeshire.

The acquisition, which will form part of LGC’s Health Sciences division, will enable LGC to provide an enhanced range of products and services to the pharmaceutical sector including bioanalysis, materials science and reference materials amongst others.

Under the terms of the transaction, Quotient and LGC have committed to collaborate as preferred partners on the provision of Bioanalytical Sciences.

This will enable clients to continue to benefit from the early development services offered by the Quotient group including clinical trials, metabolism and radiolabelling.

The Bioanalytical Sciences business will continue to trade using the “Quotient” name under its new ownership for the time being.

The transaction follows the sale two years ago by Quotient to LGC of HFL Sport Science, which is also based at the Fordham site.

Jeremy Cook, Managing Director of LGC’s Health Sciences said, “We’re delighted to have acquired Quotient Bioanalytical Sciences, a high quality business which is complementary to our existing activities. We continue to develop our range of first-rate services in the pharmaceutical, biotechnology and agrochemical sectors by offering our customers a unique mix of technical experience, leading edge facilities and knowledgeable people.”

Dr Steve Pleasance, Managing Director of Quotient Bioanalytical Sciences said “LGC’s focus on complex analytical chemistry, high quality science and service delivery make them a natural home for our business. Both our organizations have reputations built upon quality and innovation and LGC’s global presence will help support the continued growth of services to our customers.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quotient Clinical and Bend Research Announce Collaboration To Accelerate Advancement of New Medicines
Complementary Capabilities Will Cut Development Time and Expand Options for a Wide Range of Drugs.
Monday, November 15, 2010
Quotient Delivers new Insight into Safety and Efficacy of Cardiovascular, Diabetes and Obesity Drugs
Data from Quotient Bioresearch’s new extended lipid marker screen for assessing drug safety and efficacy was presented at the Institute of Biomedical Sciences (IBMS) annual congress in Birmingham (UK) this week (28 – 30 September 2009).
Thursday, October 01, 2009
High-throughput Biomarker Analysis Delivers Maximum Information from Each Sample
Quotient Bioresearch highlights its new multiplexed assays at Biomarker World Congress 2009.
Thursday, June 11, 2009
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!